title: Very-low-dose combination of perindopril and indapamide as a novel strategy in first-line management of hypertension.
abstract: Most patients with hypertension will need, at some stage, more than one drug to lower their blood pressure. Although monotherapy is still the preferred option for first-line treatment of hypertension, low-dose combination therapy as the initial medication has been increasingly recommended by National and International Guidelines. The use of perindopril/indapamide is an example of such a combination which contains 2 mg of the angiotensin converting enzyme inhibitor perindopril and 0.625 mg of the diuretic indapamide, these doses being respectively half and a quarter of the usual doses in monotherapy. This combination appears to lower blood pressure effectively with a good safety profile. It can be used in the elderly and also in patients with reduced renal function. Studies are underway to assess its efficacy on target organ damage.
authors.affiliation: Department of Medicine, University Hospital Maastricht, The Netherlands. p.deleeuw@intmed.unimaas.nl
authors.forename: P W
authors.initials: PW
authors.lastname: de Leeuw
mesh_terms: D000806:Angiotensin-Converting Enzyme Inhibitors / Q000493:pharmacokinetics / Q000592:standards / Q000627:therapeutic use*; D000959:Antihypertensive Agents / Q000493:pharmacokinetics / Q000592:standards / Q000627:therapeutic use*; D001794:Blood Pressure / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D007190:Indapamide / Q000493:pharmacokinetics / Q000592:standards / Q000627:therapeutic use*; D020913:Perindopril / Q000493:pharmacokinetics / Q000592:standards / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D007190:Indapamide; D020913:Perindopril